HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Fibroblast growth factor receptor 3 activation plays a causative role in urothelial cancer pathogenesis in cooperation with Pten loss in mice.

Abstract
Although somatic mutations and overexpression of the tyrosine kinase fibroblast growth factor receptor 3 (FGFR3) are strongly associated with bladder cancer, evidence for their functional involvement in the pathogenesis remains elusive. Previously we showed that activation of Fgfr3 alone is not sufficient to initiate urothelial tumourigenesis in mice. Here we hypothesize that cooperating mutations are required for Fgfr3-dependent tumourigenesis in the urothelium and analyse a mouse model in which an inhibitor of Pi3k-Akt signalling, Pten, is deleted in concert with Fgfr3 activation (UroIICreFgfr3(+/) (K644E) Pten(flox) (/flox)). Two main phenotypical characteristics were observed in the urothelium: increased urothelial thickness and abnormal cellular histopathology, including vacuolization, condensed cellular appearance, enlargement of cells and nuclei, and loss of polarity. These changes were not observed when either mutation was present individually. Expression patterns of known urothelial proteins indicated the abnormal cellular differentiation. Furthermore, quantitative analysis showed that Fgfr3 and Pten mutations cooperatively caused cellular enlargement, while Pten contributed to increased cell proliferation. Finally, FGFR3 overexpression was analysed along the level of phosphorylated mTOR in 66 T1 urothelial tumours in tissue microarray, which supported the occurrence of functional association of these two signalling pathways in urothelial pathogenesis. Taken together, this study provides evidence supporting a functional role of FGFR3 in the process of pathogenesis in urothelial neoplasms. Given the wide availability of inhibitors specific to FGF signalling pathways, our model may open the avenue for FGFR3-targeted translation in urothelial disease.
AuthorsMona Foth, Imran Ahmad, Bas W G van Rhijn, Theodorus van der Kwast, Andre M Bergman, Louise King, Rachel Ridgway, Hing Y Leung, Sioban Fraser, Owen J Sansom, Tomoko Iwata
JournalThe Journal of pathology (J Pathol) Vol. 233 Issue 2 Pg. 148-58 (Jun 2014) ISSN: 1096-9896 [Electronic] England
PMID24519156 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2014 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Chemical References
  • Biomarkers, Tumor
  • mTOR protein, mouse
  • Phosphatidylinositol 3-Kinase
  • Fgfr3 protein, mouse
  • Receptor, Fibroblast Growth Factor, Type 3
  • Proto-Oncogene Proteins c-akt
  • TOR Serine-Threonine Kinases
  • PTEN Phosphohydrolase
  • Pten protein, mouse
Topics
  • Animals
  • Biomarkers, Tumor (genetics, metabolism)
  • Cell Differentiation
  • Cell Proliferation
  • Cell Size
  • Cell Transformation, Neoplastic (genetics, metabolism, pathology)
  • Disease Models, Animal
  • Genetic Predisposition to Disease
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Mutation
  • PTEN Phosphohydrolase (deficiency, genetics)
  • Phenotype
  • Phosphatidylinositol 3-Kinase (metabolism)
  • Phosphorylation
  • Proto-Oncogene Proteins c-akt (metabolism)
  • Receptor, Fibroblast Growth Factor, Type 3 (deficiency, genetics, metabolism)
  • Signal Transduction
  • TOR Serine-Threonine Kinases (metabolism)
  • Urinary Bladder (enzymology, pathology)
  • Urinary Bladder Neoplasms (enzymology, genetics, pathology)
  • Urothelium (enzymology, pathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: